蔡鹏律师专精于网络安全和数据保护、知识产权、合规与监管领域，涉及人工智能、TMT、高端制造、金融、医疗健康等行业。在深度参与有关立法及实践的基础上，蔡鹏律师长期以来致力于帮助客户解决其在面临强监管、IPO、产品和服务“走出去”、数字化转型、平台治理等方面所面临的既紧迫、又富有挑战性的诸如数据合规、TMT合规、知识产权诉讼与合规等相关法律问题。

蔡鹏律师擅长解决基于互联网、大数据和人工智能技术引发的数据安全风险与合规挑战，他也擅长解决企业在数字化转型、人工智能开发和利用中各类合规风险的解决以及交易模式的构建和安排。

基于其在人工智能、数据保护与科技领域的突出实践经验，蔡鹏律师于2024年被北京市人民政府聘为第四届政府立法工作法律专家委员会委员。蔡鹏律师的执业不仅被学习强国、21世纪、南华早报、路透社等国内外多家媒体报道和采访，而且在主流的第三方评级机构如钱伯斯、Legal500以及ALB评选中也屡获荣誉。

于治国律师分别于对外经济贸易大学和美国乔治城大学获得法律硕士学位。

于律师主要从事国际贸易、争议解决、知识产权等法律事务。于律师多年从事国际经贸法律工作，具有深厚的理论功底和丰富的实践经验。

在国际贸易领域，于律师具有丰富的经验，熟悉中国、美国和欧盟等重要经济体的贸易法律和执法特点。他曾代表中国政府和企业参与中美、中欧等经贸摩擦大案要案的磋商和处理工作。他也曾是我国资深的贸易执法官员，主持和参与我国国际贸易相关法律执法和监管工作。

在国际争议解决领域，于律师作为我国政府律师，参与了十余起与中国有关的WTO争端解决案件。此外在国际投资争端解决，他也曾在世界银行参与投资争端，有丰富的实践经验。

于律师还兼任任天津市仲裁委员会仲裁员、澜湄国际仲裁院仲裁员，以及清华大学国际争端研究院课题组专家、美国乔治城大学国际经济法学会研究员和商务部国际商务官员研修基地客座教授等。
于律师先后出版了《贸易救济中的产业损害调查—WTO与中国》和《国际投资争端法律事务指南》等专著。

Chuan Sun is the Managing Partner of Morrison Foerster’s Shanghai office. He focuses his practice on life sciences and sophisticated technology, media, and telecom (TMT) transactions, complex IP/commercial matters, and cross-border M&A transactions across Greater China.

Chuan has significant experience in strategic corporate-commercial, life sciences and technology transactions, including pharma collaboration and licensing, pharmacovigilance, clinical trial, clinical supply, manufacturing, distribution, supply and franchising arrangements, and IP licensing arrangements across multiple industries. His life sciences, TMT and IP regulatory experience includes human genetic resources, telecommunications, e-commerce, internet, cyber security, data privacy, and cloud computing, as well as telematics.

Chuan regularly advises multinational corporations, state-owned enterprises, private companies and PE/VC firms in complex cross-border M&A transactions, joint ventures, strategic alliances and business separation transactions.

He has more than 20 years of experience in both Asia and the United States. Prior to joining Morrison Foerster, he worked in the Hong Kong office of a Magic Circle firm and the Chicago office of another leading international firm.

Chuan has been named as Dealmaker of Asia 2024 by Asian Legal Business. He recently advised Ensem Therapeutics, Inc., a biotechnology company focusing on high‑value and difficult-to-drug oncology targets, on its partnership with BeiGene, Ltd., a global biotechnology company. This deal has won China Business Law Journal’s Deals of the Year Award 2024.